Advanced cervical cancer: how to interpret the new standard of care

Home Page
About
Submit A Journal
Submit A Conference
Submit Paper/Book
- Submit a Preprint
- Submit a Book
Contact

Journal of Health Sciences and Medicine
Cilt: 8 Sayı: 3
Advanced cervical cancer: how to interpret the new standard of care

Advanced cervical cancer: how to interpret the new standard of care

Authors : Seda Kahraman, Hüseyin Atacan

Pages : 535-535

Doi:10.32322/jhsm.1638213

View : 57 | Download : 41

Publication Date : 2025-05-30

Article Type : Other Papers

Abstract :As pivotal practice-changing studies, the KEYNOTE-826 (KN826) and BEATcc trials provided the opportunity to add immune checkpoint inhibitors (ICPIs) to the combination of platinum-taxane doublet chemotherapy and bevacizumab, which has been the standard of care for advanced cervical cancer for many years. Combination with ICPI represents the current benchmark for the first-line treatment of advanced cervical cancer. However, there are still issues that need to be questioned in terms of precision medicine. Studies that are not limited by the selection criteria of randomized clinical trials, reflect real-life practices, and measure outcomes for larger patient groups with more balanced representation of different subgroups would be valuable.
Keywords : metastatik serviks kanseri, immünoterapi, klinik çalışma hasta alt grupları

ORIGINAL ARTICLE URL

* There may have been changes in the journal, article,conference, book, preprint etc. informations. Therefore, it would be appropriate to follow the information on the official page of the source. The information here is shared for informational purposes. IAD is not responsible for incorrect or missing information.